The job hunt for a spot on the Food and Drug Administration’s (FDA) new hiring board has been a controversial issue for several months now.
Many in Congress have voiced their concerns over how this controversial process would affect the economy.
The FDA hired contractors in order to fill several key roles in the new agency.
Those jobs, however, are in the hands of private contractors, not the FDA itself.
That has created a conflict of interest for the agency.
The hiring board is a public body created by Congress and appointed by the president, meaning that anyone, including the president himself, can hire, fire, or appoint the board.
However, it is up to the FDA to make sure the hiring process is fair and impartial.
According to the agency’s website, the board is “comprised of representatives from various federal agencies who will review and recommend to the President any qualified candidates to fill positions on the board.”
However, in a recent statement, FDA said that the hiring board’s members “are not FDA officials and do not hold the authority to appoint any individual to the board or any other position of authority.”
The agency’s statement was also criticized by some in Congress, which say that the board members have not held the authority needed to make appointments.
“The hiring process has become so politicized that it is impossible to have a fair, impartial hiring process,” Sen. Bernie Sanders (I-VT) said.
The agency has defended the hiring of the private contractors and called out the critics for what it says is a lack of transparency.
In a statement, the FDA said:”The Board of Directors is comprised of members of the FDA and is comprised entirely of people who have worked on the agency for years.
While there are many different groups of people with expertise on the FDA, they have all been involved with the FDA for decades, including at every level.
As a result, there are numerous diverse viewpoints on all aspects of the process.”
The FDA has also said that it plans to hold a public hearing on the hiring practices of the board, and has scheduled one in Washington, D.C., on May 19.
The agency has not yet made any announcements about the public hearing.
Follow Josh on Twitter at @JoshGonzalez.